美国IDSA念珠菌感染临床指南2009版

David

Clinical Infectious Diseases 2009;48:503–535 © 2009 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2009/4805-0001$15.00

IDSA GUIDELINES
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of AmericaPeter G. Pappas,1
Carol A. Kauffman,2
David Andes,4
Daniel K. Benjamin, Jr.,5
Thierry F. Calandra,11
John E. Edwards, Jr.,6
Scott G. Filler,6
John F. Fisher,7
Bart‐Jan Kullberg,12
Luis Ostrosky‐Zeichner,8
Annette C. Reboli,9
John H. Rex,13
Thomas J. Walsh,10 and
Jack D. Sobel3
1University of Alabama at Birmingham, Birmingham; 2University of Michigan and Ann Arbor Veterans Administration Health Care System, Ann Arbor, and 3Wayne State University, Detroit, Michigan; 4University of Wisconsin, Madison; 5Duke University Medical Center, Durham, North Carolina; 6Harbor–University of California at Los Angeles Medical Center, Torrance; 7Medical College of Georgia, Augusta; 8University of Texas at Houston, Houston; 9Cooper Hospital, Camden, New Jersey; 10National Cancer Institute, Bethesda, Maryland; 11Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 12Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands; and 13Astra Zeneca Pharmaceuticals, Manchester, United Kingdom
Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis in high‐risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults. This new information is incorporated into this revised document.